Novavax Inc (NVAX.O) said on Monday it had filed for U.S. authorization for use of its COVID-19 vaccine as a booster dose in people who had either received its shots or a different vaccine.
The application to the U.S. Food and Drug Administration comes in the face of a slow rollout in the United States, where the Novavax vaccine was authorized in July, despite expectations that it would convince vaccine skeptics to get inoculated.
“It’s important for people to have a choice as they evaluate how to stay protected against COVID-19,” Chief Executive Officer Stanley Erck said in a statement, referring to the Novavax vaccine that uses a traditional technology.